269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群 Pyogenic arthritis Clinical trials / Disease details
臨床試験数 : 23 / 薬物数 : 30 - (DrugBank : 12) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 106
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03072953 (ClinicalTrials.gov) | June 7, 2017 | 17/2/2017 | Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum | A Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (APD334) in Patients With Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: APD334 | Arena Pharmaceuticals | NULL | Terminated | 18 Years | 80 Years | All | 2 | Phase 2 | Australia;New Zealand |